Vaccination on the territory of the Czech Republic is allowed only with fully registered vaccines that have passed the European Medicines Agency (EMA) approval and have been approved by the European Commission for use within the EU.
| Vaccine name | Pharmaceutical company | Marking at registration for vaccination | Indications (age) | Vaccine type |
|---|---|---|---|---|
|
Comirnaty |
Pfizer/BioNTech |
COMIRNATY/Pfizer |
from 6 months |
mRNA |
|
Basic vaccination schedule Children aged six months to 4 years receive Comirnaty in three doses of 3 micrograms each. The first two doses are given three weeks apart, and the third dose is given at least eight weeks after the second dose. Injections may be given into the muscles of the upper arm or thigh. The vaccine is labeled COMIRNATY/Pfizer mini CO16 when registered for vaccination. In adults and children five years and older, Comirnaty is given in two doses, usually administered by injection into a muscle in the upper arm, three weeks apart. Adults and adolescents aged 12 years and over are given a dose of 30 micrograms, and children aged 5 to 11 years are given a dose of 10 micrograms. The vaccine for children 5-15 is labeled COMIRNATY/Pfizer junior when registered for the vaccine. Persons with a severely weakened immune system aged five years and older may be given an additional dose at least 28 days after the second dose. Booster dose* For children aged 5 to 11 years, the booster dose can be given at least six months after the baseline vaccination. Adults and adolescents 12 years and older may receive the first booster dose three months after completing the basic vaccination schedule.
|
||||
|
Spikevax |
Moderna |
SPIKEVAX/Moderna |
from 6 years |
mRNA |
|
Basic vaccination schedule Spikevax is administered in two doses, usually injected into a muscle in the upper arm or the thigh in young children, 28 days apart. Adults and adolescents aged 12 years and over are given a dose of 100 micrograms, and children aged 6 to 11 years are given a dose of 50 micrograms. Booster dose* A booster dose of Spikevax might be administered to adults and adolescents aged 12 years and older if the baseline vaccination was administered with Spikevax or another mRNA vaccine or adenovirus vector vaccine against the covid-19 disease. |
||||
|
Vaxzevria |
AstraZeneca |
Vaxzevria/AstraZeneca |
from 18 years |
vector |
|
The vaccine is currently unavailable in the Czech Republic. Basic vaccination schedule Vaxzevria is administered in two doses that are usually injected into a muscle in the upper arm. The second dose should be administered between 4 and 12 weeks after the first dose. Booster dose* A booster dose of Vaxzevria may be given if the baseline vaccination was given with Vaxzevria or another mRNA vaccine against covid-19. The booster dose should be given at least three months after the baseline vaccination. |
||||
|
JCOVDEN |
Janssen (Johnson&Johnson) |
Jcovden/Janssen |
from 18 years |
vector |
|
Basic vaccination schedule The JCOVDEN vaccine is given in a single dose that is usually injected into a muscle in the upper arm. Booster dose* A booster dose of Jcovden can be given at least two months after the first dose of Jcovden. Suppose the baseline vaccination was administered with one of the EU-marketed covid-19 mRNA vaccines. In that case, a booster dose of Jcovden may also be administered according to the dosing interval listed in the mRNA vaccine Summary of Product Characteristics. |
||||
|
Nuvaxovid |
Novavax |
NOVAVAX/Nuvaxovid |
from 12 years |
protein-based |
|
The vaccine is currently unavailable in the Czech Republic. Basic vaccination schedule Nuvaxovid vaccine is given in two doses, usually injected into a muscle in the upper arm, three weeks apart. Booster dose* A booster dose of Nuvaxovid may be given approximately six months after the second dose of Nuvaxovid. If the baseline vaccination was administered with one of the mRNA or adenoviral vector vaccines against covid-19, a booster dose of Nuvaxovid might also be administered according to the dosing interval specified in the Summary of Product Characteristics of the baseline vaccine. |
||||
|
Comirnaty Original/ Omicron BA.1** |
Pfizer/BioNTech |
COMIRNATY/Pfizer BA.1 |
from 12 years |
mRNA |
|
For re-vaccination only after completion of the basic vaccination! A booster dose of Comirnaty Original/Omicron BA.1 (30 micrograms) may be administered to persons aged 12 years and older at least three months after the primary vaccination or booster dose of COVID-19. |
||||
|
Spikevax bivalent Original/Omicron BA.4-5** |
Moderna |
SPIKEVAX/Moderna BA.4/BA.5 |
from 12 years |
mRNA |
|
For re-vaccination only after completion of the basic vaccination! The booster dose of Spikevax bivalent Original/Omicron BA.4-5 may be administered to adults and teenagers aged 12 years and older at least 3 months after the baseline vaccination or booster dose of COVID-19. |
||||
|
Comirnaty Original/ Omicron BA.4-5** |
Pfizer/BioNTech |
COMIRNATY/Pfizer BA.4/BA.5 |
from 5 years |
mRNA |
|
For re-vaccination only after completion of the basic vaccination! A booster dose of Comirnaty Original/Omicron BA.4-5 (10 micrograms) may be administered to persons aged 5 to 11 years at least three months after the baseline vaccination or after a booster dose of COVID-19. A booster dose of Comirnaty Original/Omicron BA.4-5 (30 micrograms) may be administered to persons aged 12 years and older at least three months after the baseline vaccination or booster dose of COVID-19. |
||||
|
VidPrevtyn Beta |
Sanofi |
SANOFI/VidPrevtyn |
from 18 years |
protein-based |
|
For re-vaccination only after completion of the basic vaccination! VidPrevtyn Beta is given by injection, usually into a muscle in the upper arm. It can be given as a single booster dose at least four months after administering a previous mRNA or adenoviral vector vaccine against COVID-19. |
||||
*Does not include the possibility of combining vaccines; the intervals correspond to those indicated in the summary of product characteristics when the same vaccine is administered